Another of our shares highlighted in The Times this morning.
Dechra is a multibillion-pound pet medicines business and is in rude health after gobbling up rivals and delivering strong annual trading.
The company said that it had increased group revenue by about 17% in the year to the end of June. European pharmaceuticals revenue growth was about 18% and in North America it was about 15%
Dechra has been transformed into a near £3 billion UK veterinary pharmaceuticals company, boosted by a series of deals, including last year's £298 million acquisitions of AST and Le Vet, the European vet pharma companies.
Up almost 3% today with hopefully more to come.
Well done China Dolls.
Comentários